Sean Sheridan and Zlatina Dobreva discuss the importance of licensing intellectual property in the life sciences industry in the successful commercialization of early-stage therapeutics. Different licensing structures reflect the need for licensors and licensees to consider the range of paths for early-stage biotechnology development and then take all available and mutually agreeable steps to protect their interests. Read the full piece below.
Vaccines year in review 2024
Engagement highlights CRA has conducted numerous vaccines projects this year. Here, we highlight some of the most impactful engagements from our strategy and...